Tyrosine Kinase Inhibitors Treatment in CML Patients with Deep Molecular Response

Tyrosine Kinase Inhibitors Treatment in CML Patients with Deep Molecular Response

ASHReport

3 years
553 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Francois-Xavier Mahon, MD, PhD of University of Bordeaux, presents a press briefing on Cessation of Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia Patients with Deep Molecular Response: Results of the Euro-Ski Trial at the 58th ASH Annual Meeting in San Diego, CA.
Up Next Autoplay